Chemically modified small molecules
AssigneeNektar Therapeutics
InventorsC. Simone Fishburn, David Lechuga-Ballesteros, Tacey X. Viegas, Mei-Chang Kuo, Hema Gursahani, Chester Leach, Yuan Song
Life of this patent
Estimating the term…
Loading patent…
AssigneeNektar Therapeutics
InventorsC. Simone Fishburn, David Lechuga-Ballesteros, Tacey X. Viegas, Mei-Chang Kuo, Hema Gursahani, Chester Leach, Yuan Song
Estimating the term…
Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchioalveolar lavage followed by assaying residual lung material.
1-38. (canceled)
A pharmaceutical compound for pulmonary administration comprising a drug covalently attached to polyethylene glycol, wherein the pharmaceutical compound has a net hydrophilic character, wherein the drug has a molecular weight of less than about 1500 Daltons, and wherein the weight average molecular weight of the polyethylene glycol is from 1000 Daltons to about 3500 Daltons.
Dependencies are inferred from the claim text.